//www.snoollab.com:80/handle/2SGJ60CL/186827 Sat, 27 Jul 2024 20:19:28 GMT 2024-07-27T20:19:28Z //www.snoollab.com:80/handle/2SGJ60CL/789440 题名: A chest CT-based nomogram for predicting survival in acute myeloid leukemia ( vol 24 , 458 , 2024) 作者: Yi, Xiaoping; Zhan, Huien; Lyu, Jun; Du, Juan; Dai, Min; Zhao, Min; Zhang, Yu; Zhou, Cheng; Xu, Xin; Fan, Yi; Li, Lin; Dong, Baoxia; Jiang, Xinya; Xiao, Zeyu; Zhou, Jihao; Zhao, Minyi; Zhang, Jian; Fu, Yan; Chen, Tingting; Xu, Yang; Tian, Jie; Liu, Qifa; Zeng, Hui Fri, 19 Jul 2024 09:31:28 GMT //www.snoollab.com:80/handle/2SGJ60CL/789440 2024-07-19T09:31:28Z //www.snoollab.com:80/handle/2SGJ60CL/789434 题名: Arctigenin derivative A-1 ameliorates motor dysfunction and pathological manifestations in SOD1<SUP>G93A</SUP> transgenic mice via the AMPK/SIRT1/PGC-1α and AMPK/SIRT1/IL-1β/NF-κB pathways( vol 30 , e14692 , 2024) 作者: Xiong, Bocheng; Yang, Chao; Yang, Xiao; Luo, Song; Li, Shangming; Chen, Chongyang; He, Kaiwu; Nie, Lulin; Li, Peimao; Li, Shupeng; Huang, Haiyan; Liu, Jianjun; Zhang, Zaijun; Xie, Yongmei; Zou, Liangyu; Yang, Xifei Fri, 19 Jul 2024 09:30:41 GMT //www.snoollab.com:80/handle/2SGJ60CL/789434 2024-07-19T09:30:41Z //www.snoollab.com:80/handle/2SGJ60CL/789431 题名: Corrigendum to “Platelet membrane fusion liposome loaded with type I AIE photosensitizer to induce chemoresistance cancer pyroptosis and immunogenic cell death for enhancing cancer immunotherapy” [Chem. Eng. J. 476 (2023) 146276] (Chemical Engineering Journal (2023) 476, (S1385894723050076), (10.1016/j.cej.2023.146276)) 作者: Chen，Hao; Luo，Xi; Huang，Qinghua; Liu，Zeming; Lyu，Meng; Chen，Dexin; Mo，Jianlan; Zhu，Daoming 摘要: The authors regret that the correct affiliation “a” which has been updated as above. The authors would like to apologise for any inconvenience caused. Fri, 19 Jul 2024 09:30:26 GMT //www.snoollab.com:80/handle/2SGJ60CL/789431 2024-07-19T09:30:26Z //www.snoollab.com:80/handle/2SGJ60CL/789426 题名: Effects of carrimycin on biomarkers of inflammation and immune function in tumor patients with sepsis: A multicenter double-blind randomized controlled trial 作者: Nan, Chuanchuan; Zhang, Xiaowu; Huang, Wei; Zhu, Biao; Zhao, Jianghong; Lu, Song; Xian, Lewu; Liu, Kaizhong; Ma, Gang; Yang, Wei; Huang, Mingguang; Zhou, Dongmin; Zhang, Ming; Duan, Yan; Wu, Guixin; Jiang, Zhengying; Zhang, Li; He, Xinrong; Chen, Yuhong; Xing, Xuezhong; Wang, Changsong; Wang, Donghao; Yu, Kaijiang 摘要: Carrimycin is a potential immune-regulating agent for sepsis in patients with tumors. In this study, we inves-tigated its effects on inflammation and immune function in tumor patients with sepsis. In total, 120 participants were randomized to receive either carrimycin treatment (400 mg/day) (n = 62) or placebo (n = 58) for 7 days. The primary outcomes were immune-related indicators. Subsequently, patients were stratified into two sub-groups (CD4 < 38.25% and CD8 < 25.195%). Ninety-nine participants were analyzed: 47 and 52 in the carrimycin and placebo groups, respectively. HLA-DR levels were rapidly increased in the carrimycin group; however, the placebo group initially experienced a decline in HLA-DR level at 1 day after administration. In the subgroup with CD4 < 38.25%, the carrimycin group exhibited significantly higher HLA-DR levels than the placebo group (2.270, P = 0.023) 1 day after administration and the degree of increase in HLA-DR in the carrimycin group was higher than that in the placebo group (2.057, P = 0.040). In the CD8 < 25.195% subgroup, the carrimycin group demonstrated significantly higher levels of CD8+ T cells than the placebo group at 3 (2.300, P = 0.027) and 5 (2.106, P = 0.035) days after administration. Carrimycin intervention led to significant reductions in the SOFA, APACHE II, PCT, and CRP levels. No adverse events were observed. In tumor patients with sepsis, particularly in those experiencing immunological suppression, carrimycin effectively regulates immune responses by increasing HLA-DR and CD8(+) T cell levels and plays an anti-infective role, reducing disease severity. Fri, 19 Jul 2024 09:14:53 GMT //www.snoollab.com:80/handle/2SGJ60CL/789426 2024-07-19T09:14:53Z //www.snoollab.com:80/handle/2SGJ60CL/789422 题名: Ventromedial hypothalamus relays chronic stress inputs and exerts bidirectional regulation on anxiety state and related sympathetic activity 作者: Shao, Jie; Chen, Yan; Gao, Dashuang; Liu, Yunhui; Hu, Nan; Yin, Lianghong; Zhang, Xinzhou; Yang, Fan 摘要: Chronic stress can induce negative emotion states, including anxiety and depression, leading to sympathetic overactivation and disturbed physiological homeostasis in peripheral tissues. While anxiety-related neural circuitry integrates chronic stress information and modulates sympathetic nervous system (SNS) activity, the critical nodes linking anxiety and sympathetic activity still need to be clarified. In our previous study, we demonstrated that the ventromedial hypothalamus (VMH) is involved in integrating chronic stress inputs and exerting influence on sympathetic activity. However, the underlying synaptic and electrophysiological mechanisms remain elusive. In this study, we combined in vitro electrophysiological recordings, behavioral tests, optogenetic manipulations, and SNS activity analyses to explore the role of VMH in linking anxiety emotion and peripheral SNS activity. Results showed that the VMH played an important role in bidirectionally regulating anxiety-like behavior and peripheral sympathetic excitation. Chronic stress enhanced excitatory inputs into VMH neurons by strengthening the connection with the paraventricular hypothalamus (PVN), hence promoting anxiety and sympathetic tone outflow, an important factor contributing to the development of metabolic imbalance in peripheral tissues and cardiovascular diseases. Fri, 19 Jul 2024 09:13:53 GMT //www.snoollab.com:80/handle/2SGJ60CL/789422 2024-07-19T09:13:53Z //www.snoollab.com:80/handle/2SGJ60CL/789417 题名: Development of a quadruple qRT-PCR assay for simultaneous identification of hypervirulent and carbapenem-resistant <i>Klebsiella pneumoniae</i> 作者: Xu, Zhixiang; Li, Baisheng; Jiang, Yushan; Huang, Jia; Su, Lebin; Wu, Weibo; Pang, Qilin; Li, Zhuolin; Zhang, Jiaqi; Li, Xiaohe; Wang, Jun; Cen, Fulan; Peng, Ling; Liang, Jinhu; Wang, Fuxiang; Liu, Chang; Shen, Chenguang; Liu, Yingxia; Yang, Yang 摘要: The increasing prevalence of hypervirulent (hv) and carbapenem-resistant (CR) Klebsiella pneumoniae (Kp) highlights the importance of timely and accurate differential diagnosis for epidemiological investigation and clinical management. A multiplex quantitative real-time PCR (qRT-PCR) assay for the simultaneous identification of hvKp and CR-Kp was developed and validated with excellent performance in sensitivity and specificity. Generally, the gltA gene for Kp, the iucA, rmpA and rmpA2 genes for hvKp, and the Klebsiella pneumoniae carbapenemases (KPC) gene for CR-Kp were included in the qRT-PCR assay. The detection limits for classic Kp (cKp), CR-cKp, hvKp, and CR-hvKp strains could all reach 50 genome equivalent copies and 20 CFUs per reaction with high accuracy (R-2 > 0.99) and reliability (CV values < 3%). Detection results from 84 Kp positive clinical samples showed 31 hvKp with 8 CR-hvKp and 53 cKp with 1 CR-cKp strains. The presence of virulence-associated factors for the identified hvKp and KPC genes for CR-Kp was confirmed by previously developed conventional PCR and antimicrobial susceptibility tests, respectively. Furthermore, the qRT-PCR identified hvKp strains showed mortality rates of >= 40% in the outbred murine infection model, while no death for the identified cKp strains. These results indicated that our multiplex qRT-PCR assay could accurately identify hvKp and CR-Kp strains, which will be of great use for the rapid and accurate diagnosis in a clinical setting and the surveillance of the circulating Kp. Fri, 19 Jul 2024 09:10:59 GMT //www.snoollab.com:80/handle/2SGJ60CL/789417 2024-07-19T09:10:59Z //www.snoollab.com:80/handle/2SGJ60CL/789415 题名: Human papillomavirus infection affects treatment outcomes and the immune microenvironment in patients with advanced penile squamous cell carcinoma receiving programmed cell death protein 1 inhibitor-based combination therapy 作者: Wei, Lichao; Li, Zaishang; Guo, Shengjie; Ma, Huali; Shi, Yanxia; An, Xin; Huang, Kangbo; Xiong, Longbin; Xue, Ting; Zhang, Zhiling; Yao, Kai; Luo, Junhang; Han, Hui 摘要: Background: Penile squamous cell carcinoma (PSCC) is a human papillomavirus (HPV)-associated malignancy. Immunotherapy is emerging as a potential treatment for advanced PSCC. In this study, the authors analyzed the association of HPV status with outcomes and the immune microenvironment in patients with advanced PSCC undergoing programmed cell death protein 1 (PD1) inhibitor-based combination therapy (PCT).Methods: HPV status was assessed using quantitative polymerase chain reaction in 87 patients with advanced PSCC treated with PCT. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) in the HPV+ and HPV- groups were compared. Additionally, bulk RNA sequencing was performed to investigate the potential impact of HPV on the immune microenvironment in advanced PSCC.Results: Among patients receiving first-line PCT, ORR (91.7% vs. 64.6%, p = .014) and DCR (100.0% vs. 79.2%, p = .025) in the HPV+ group were higher compared to the HPV- group. Kaplan-Meier curves demonstrated that the HPV+ group exhibited superior PFS (p = .005) and OS (p = .004) for patients in the first-line setting. However, these advantages of HPV infection were not observed in multi-line PCT (p > .050). HPV status remained an independent prognostic factor for predicting better ORR (p = .024), PFS (p = .002), and OS (p = .020) in the multivariate analyses. Landmark analyses showed that the HPV-induced superiority of PFS occurred at an early stage (within 3 months) and OS occurred at a relatively late stage (within 9 months). Bioinformatic analyses identified potential immune-activated genes (GLDC, CYP4F12, etc.) and pathways (RAGE, PI3K/AKT, etc.), antitumor immune cell subtypes, and lower tumor immune dysfunction and exclusion scores in HPV+ tissues.Conclusions: HPV infection may confer treatment efficacy and survival benefits in patients with advanced PSCC receiving first-line PCT because of the possible stimulation of the antitumor immune microenvironment. Fri, 19 Jul 2024 09:09:13 GMT //www.snoollab.com:80/handle/2SGJ60CL/789415 2024-07-19T09:09:13Z //www.snoollab.com:80/handle/2SGJ60CL/789414 题名: Mpox (formerly monkeypox): pathogenesis, prevention, and treatment 作者: Lu, Junjie; Xing, Hui; Wang, Chunhua; Tang, Mengjun; Wu, Changcheng; Ye, Fan; Yin, Lijuan; Yang, Yang; Tan, Wenjie; Shen, Liang 摘要: In 2022, a global outbreak of Mpox (formerly monkeypox) occurred in various countries across Europe and America and rapidly spread to more than 100 countries and regions. The World Health Organization declared the outbreak to be a public health emergency of international concern due to the rapid spread of the Mpox virus. Consequently, nations intensified their efforts to explore treatment strategies aimed at combating the infection and its dissemination. Nevertheless, the available therapeutic options for Mpox virus infection remain limited. So far, only a few numbers of antiviral compounds have been approved by regulatory authorities. Given the high mutability of the Mpox virus, certain mutant strains have shown resistance to existing pharmaceutical interventions. This highlights the urgent need to develop novel antiviral drugs that can combat both drug resistance and the potential threat of bioterrorism. Currently, there is a lack of comprehensive literature on the pathophysiology and treatment of Mpox. To address this issue, we conducted a review covering the physiological and pathological processes of Mpox infection, summarizing the latest progress of anti-Mpox drugs. Our analysis encompasses approved drugs currently employed in clinical settings, as well as newly identified small-molecule compounds and antibody drugs displaying potential antiviral efficacy against Mpox. Furthermore, we have gained valuable insights from the process of Mpox drug development, including strategies for repurposing drugs, the discovery of drug targets driven by artificial intelligence, and preclinical drug development. The purpose of this review is to provide readers with a comprehensive overview of the current knowledge on Mpox. Fri, 19 Jul 2024 09:08:44 GMT //www.snoollab.com:80/handle/2SGJ60CL/789414 2024-07-19T09:08:44Z //www.snoollab.com:80/handle/2SGJ60CL/789413 题名: Circulating miRNAs act as potential biomarkers for asthma 作者: Hu, Guang; Du, Yujie; Xie, Manying; Chen, Rongchang; Shi, Fei 摘要: BackgroundIdentification of new clinical markers contributes to a better understanding of the pathogenesis of asthma. Considering the crucial role of LIGHT in asthma, it may become a potential target for asthma. The aim of current study was to determine if circulating microRNAs (miRNAs) targeting LIGHT may be used as diagnostic biomarkers to distinguish asthma.MethodsBlood serum from a cohort of 60 subjects, including 20 cases with mild asthma, 20 cases with moderate-to-severe asthma, and 20 healthy controls were included. Serum was analyzed for circulating miRNAs profiles through miRNAs microarray. Real Time PCR was conducted to verify the results of miRNA microarray. Correlations between circulating miRNAs targeting LIGHT and clinical characteristics were investigated.ResultsA total of 365 miRNAs were differentially expressed in asthma patients. Among them, miR-107 and miR-140-5p were found to target LIGHT, and varied in asthmatics. Additionally, miR-107 and miR-140-5p expressions were positively correlated with the absolute value of peripheral eosinophils. Finally, miR-140-5p and miR-107 were demonstrated to have good diagnostic efficacy for asthma (AUC= 0.8667 and 0.9400) with good sensitivity (0.8000 and 0.8667,respectively) and specificity (0.8667 and 0.867). Thus, circulating miRNAs expressed differentially between healthy control and asthma patients.ConclusionPlasma miR-140-5p and miR-107 can be used as diagnostic biomarkers to distinguish patients with asthma from healthy control, and may take part in asthma pathogenesis by negatively regulating LIGHT. Further research was needed to evaluate their roles as potential biomarkers in the diagnosis of asthma. Fri, 19 Jul 2024 09:08:37 GMT //www.snoollab.com:80/handle/2SGJ60CL/789413 2024-07-19T09:08:37Z //www.snoollab.com:80/handle/2SGJ60CL/789412 题名: The enhancement effect of small molecule Lyb24 reveals AzoR as a novel target of polymyxin B 作者: Hu, Chunxia; Zhang, Jinyong; Cui, Ruiqin; Liu, Shiyi; Huang, Ying; Zeng, Huan; Cheng, Shumin; Zhou, Guibao; Li, Jingli; Sun, Longqin; Zhao, Yan; Wang, Xiao; Liu, Jianhua; Zou, Quanming; Huang, Wei 摘要: Given the important role of polymyxin B (PB) in the treatment of drug-resistant Gram-negative bacterial infections, the emergence of PB resistance poses a serious threat to public health. Adjuvant development is a supplementary strategy that can compensate for the lack of novel antibiotics by protecting PB. In this study, we found a small molecule named Lyb24 that showed weak antibacterial activity (minimum inhibitory concentration >= 10 mu g/ml) but potentiated and revitalized the efficacy of PB against Gram-negative pathogens, including mcr-1- and mgrB-deletion-mediated PB-resistant strains. Our results showed that Lyb24 inhibits the translational levels of genes associated with the modification of lipid A. In addition, Lyb24 increases the permeability, disrupts the integrity and induces the depolarization of the membrane. We further found that both Lyb24 and PB could directly bind to AzoR and inhibit its activity. Structural analysis showed that Lyb24 binds to the isoalloxazine ring of flavin mononucleotide (FMN) through pi-pi stacking and loop eta 4 of AzoR. A pneumonia model was used to confirm that the activity against clinical PB-resistant Klebsiella pneumoniae was enhanced due to Lyb24 on PB. In conclusion, we provide a potential therapeutic regimen by combining Lyb24 and PB to treat Gram-negativeresistant bacterial infections. Our findings not only explain the synergistic effect of Lyb24, but also expand our knowledge on the mechanism of action of PB. Fri, 19 Jul 2024 09:08:01 GMT //www.snoollab.com:80/handle/2SGJ60CL/789412 2024-07-19T09:08:01Z